Day: March 29, 2022

Oramed’s Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians

– 76 Percent of the Physicians Responded They “Definitely Would” or “Probably Would” Prescribe Oramed’s Oral Insulin Candidate for Type 2 Diabetes Patients NEW YORK , March 29, 2022 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage

  • +1-844-9-ORAMED
  • office@oramed.com
  • 1185 Avenue of the Americas, New York, NY 10036 USA
Linkedin-in Facebook-f Twitter Youtube

Copyright © 2022 Oramed. | Terms & Conditions | Privacy Statement | Cookie Policy

Join our mailing list

  • +1-844-9-ORAMED
  • office@oramed.com
Linkedin-in Facebook-f Twitter Youtube
Home
About
Technology
Pipeline
Contact us
NEWS
Press Releases
In the News
Scientific Articles and Abstracts
INVESTORS
Corporate presentation
Investor Relations
SEC filings
Investor FAQ
Governance documents
Investor tools
ANNUAL SHAREHOLDER MEETING
Oravax Medical
Skip to content
Open toolbar

Accessibility Tools

  • Increase Text
  • Decrease Text
  • Grayscale
  • High Contrast
  • Negative Contrast
  • Light Background
  • Links Underline
  • Readable Font
  • Reset